Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NKT cells as an ideal anti-tumor immunotherapeutic.
Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, Taniguchi M. Fujii S, et al. Among authors: kunii n. Front Immunol. 2013 Dec 2;4:409. doi: 10.3389/fimmu.2013.00409. Front Immunol. 2013. PMID: 24348476 Free PMC article. Review.
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y. Uchida T, et al. Among authors: kunii n. Cancer Immunol Immunother. 2008 Mar;57(3):337-45. doi: 10.1007/s00262-007-0373-5. Epub 2007 Aug 10. Cancer Immunol Immunother. 2008. PMID: 17690880 Free PMC article. Clinical Trial.
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: kunii n. J Immunol. 2009 Feb 15;182(4):2492-501. doi: 10.4049/jimmunol.0800126. J Immunol. 2009. PMID: 19201905 Clinical Trial.
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells.
Kamata T, Suzuki A, Mise N, Ihara F, Takami M, Makita Y, Horinaka A, Harada K, Kunii N, Yoshida S, Yoshino I, Nakayama T, Motohashi S. Kamata T, et al. Among authors: kunii n. Cancer Immunol Immunother. 2016 Dec;65(12):1477-1489. doi: 10.1007/s00262-016-1901-y. Epub 2016 Sep 15. Cancer Immunol Immunother. 2016. PMID: 27631416 Free PMC article.
Regulatory T cells induce CD4- NKT cell anergy and suppress NKT cell cytotoxic function.
Ihara F, Sakurai D, Takami M, Kamata T, Kunii N, Yamasaki K, Iinuma T, Nakayama T, Motohashi S, Okamoto Y. Ihara F, et al. Among authors: kunii n. Cancer Immunol Immunother. 2019 Dec;68(12):1935-1947. doi: 10.1007/s00262-019-02417-6. Epub 2019 Oct 22. Cancer Immunol Immunother. 2019. PMID: 31641795 Free PMC article.
108 results